Active substance
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Afstyla | 250 IU | Powder and solvent for solution for injection · Intravenous use | 1 Vial | SAR 628.75 | Biological · Prescription | CSL | Valid |
| Afstyla | 500 IU | Powder and solvent for solution for injection · Intravenous use | 1 Vial | SAR 1257.55 | Biological · Prescription | CSL | Valid |
| Afstyla | 1000 IU | Powder and solvent for solution for injection · Intravenous use | 1 Vial | SAR 2515.00 | Biological · Prescription | CSL | Valid |
| Afstyla | 2000 IU | Powder and solvent for solution for injection · Intravenous use | 1 Vial | SAR 5030.10 | Biological · Prescription | CSL | Valid |
| Afstyla | 3000 IU | Powder and solvent for solution for injection · Intravenous use | 1 Vial | SAR 7545.00 | Biological · Prescription | CSL | Valid |
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Afstyla can be used for all age groups.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.